Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
13 mai 2024 08h30 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James...
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
10 mai 2024 08h30 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
22 mars 2024 08h30 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced...
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
18 mars 2024 08h00 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the...
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
29 janv. 2024 08h00 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it...
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
11 janv. 2024 08h15 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
18 déc. 2023 07h00 HE
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a...
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
05 déc. 2023 08h30 HE
|
Checkpoint Therapeutics, Inc
Upcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc....
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
13 nov. 2023 17h00 HE
|
Checkpoint Therapeutics, Inc
Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 Recent publication of cosibelimab pivotal trial results in the Journal for ImmunoTherapy...
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer
18 oct. 2023 08h30 HE
|
Checkpoint Therapeutics, Inc
Cosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous...